157 related articles for article (PubMed ID: 2974027)
21. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
22. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry.
Huang J; Fan G; Zhong Y; Gatter K; Braziel R; Gross G; Bakke A
Am J Clin Pathol; 2005 Jun; 123(6):826-32. PubMed ID: 15899772
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of cytoplasmic antigens in acute leukemia by flow cytometry].
Kawai S; Zha Z; Yamamoto Y; Nakadate H; Kawakami K; Kikuta A; Utsumi J; Nishikawa K; Mimaya J; Miyake M
Rinsho Ketsueki; 1993 Jan; 34(1):13-20. PubMed ID: 8450602
[TBL] [Abstract][Full Text] [Related]
25. Membrane CD22 defines circulating myeloma-related cells as mature or later B cells.
Perfetti V; Vignarelli MC; Bellotti V; Glennie MJ; Zorzoli I; Ubbiali P; Obici L; Massa M; Ippoliti G; Ascari E; Merlini G
Lab Invest; 1997 Oct; 77(4):333-44. PubMed ID: 9354768
[TBL] [Abstract][Full Text] [Related]
26. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus.
Lajaunias F; Ida A; Kikuchi S; Fossati-Jimack L; Martinez-Soria E; Moll T; Law CL; Izui S
Arthritis Rheum; 2003 Jun; 48(6):1612-21. PubMed ID: 12794829
[TBL] [Abstract][Full Text] [Related]
27. Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique.
Meijer E; Slaper-Cortenbach IC; Thijsen SF; Dekker AW; Verdonck LF
Bone Marrow Transplant; 2002 Feb; 29(4):335-9. PubMed ID: 11896431
[TBL] [Abstract][Full Text] [Related]
28. Leukemia-associated marker combinations in acute leukemia suitable for detection of minimal residual disease.
Babusíková O; Mesárosová A; Koníková M; Kusenda J; Glasová M; Klobusická M
Neoplasma; 1993; 40(5):275-81. PubMed ID: 8272155
[TBL] [Abstract][Full Text] [Related]
29. A comparison of some leucocyte differentiation markers and the adenosine deaminase and purine nucleoside phosphorylase values in B and T cell leukemias and lymphomas.
Mesárosová A; Hrivnáková A; Babusíková O
Neoplasma; 1995; 42(6):307-12. PubMed ID: 8592572
[TBL] [Abstract][Full Text] [Related]
30. T cell receptor expression can switch on and off at a posttranslational level.
Maecker HT; Jokinen DM; Fisher RI
J Immunol; 1992 Sep; 149(5):1619-25. PubMed ID: 1387145
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of the B cell-restricted molecule CD22 on neonatal B lymphocytes depending upon antigen stimulation.
Viemann D; Schlenke P; Hammers HJ; Kirchner H; Kruse A
Eur J Immunol; 2000 Feb; 30(2):550-9. PubMed ID: 10671211
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibody studies in B(non-T)-cell malignancies.
Shimoyama M; Minato K; Tobinai K; Nagai M; Hirose M
Jpn J Clin Oncol; 1983 Sep; 13(3):477-88. PubMed ID: 6417373
[TBL] [Abstract][Full Text] [Related]
33. Quantitative immunocytofluorometry--new parameters for the definition of leukemia cells.
Babusíková O; Glasová M; Stasáková J; Kusenda J; Koníková E
Neoplasma; 1997; 44(6):348-55. PubMed ID: 9605006
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of different fixation-permeabilization methods for simultaneous detection of surface, cytoplasmic markers and DNA analysis by flow cytometry in some human hematopoietic cell lines.
Glasová M; Koníková E; Kusenda J; Babusíková O
Neoplasma; 1995; 42(6):337-46. PubMed ID: 8592577
[TBL] [Abstract][Full Text] [Related]
35. Constitutive endocytosis and degradation of CD22 by human B cells.
Shan D; Press OW
J Immunol; 1995 May; 154(9):4466-75. PubMed ID: 7722303
[TBL] [Abstract][Full Text] [Related]
36. B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking.
Chaouchi N; Vazquez A; Galanaud P; Leprince C
J Immunol; 1995 Apr; 154(7):3096-104. PubMed ID: 7534787
[TBL] [Abstract][Full Text] [Related]
37. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
38. Detection of cytoplasmic and surface membrane markers in cells of some human hematopoietic cell lines.
Koníková E; Babusíková O; Kusenda J; Glasová M
Neoplasma; 1992; 39(6):337-42. PubMed ID: 1491722
[TBL] [Abstract][Full Text] [Related]
39. CD3-negative, CD20-positive T-cell prolymphocytic leukemia: case report and review of the literature.
Tamayose K; Sato N; Ando J; Sugimoto K; Oshimi K
Am J Hematol; 2002 Dec; 71(4):331-5. PubMed ID: 12447967
[TBL] [Abstract][Full Text] [Related]
40. Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells.
Law CL; Aruffo A; Chandran KA; Doty RT; Clark EA
J Immunol; 1995 Oct; 155(7):3368-76. PubMed ID: 7561031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
